Rotterdam-based Delta Diagnostics, a company that develops integrated photonics to create highly sensitive and selective biosensors, announced on Tuesday, May 9, that it has raised €5.25M in a Series A round of funding.
The investment came from i&i Biotech Fund (a Fund supported by an investment from the EIF), Oost NL, InnovationQuarter and PhotonDelta.
Karel Kubias, Partner at i&i Biotech Fund, says, “We firmly believe that Delta’s technology can effectively bring a significant improvement in the biosensing arena. We are convinced, the interest of industrial partners for this technology maintains the committed team of Delta on the right trajectory to future success.”
What does Delta Diagnostics offer?
Founded in 2018 by Bart de Boer, Delta Diagnostics aims to transform biosensing technology by making label-free, multiplexed biosensors and devices available to everyone. The firm is a spin-off of TNO.
A biosensor device detects the presence of an analyte in a biological or chemical process and produces signals corresponding to that concentration. Applications for biosensors include illness monitoring, drug discovery, and the detection of pollutants, disease-causing microorganisms, and markers that are indicators of disease in body fluids (blood, urine, saliva, and sweat).
Using photonic integrated circuits, the company’s approach to biosensing decreases the complexity and cost of typical lab approaches.
A photonic integrated circuit is a microchip that has two or more photonic components that work together to produce a functional circuit.
Delta Diagnostics wants to empower researchers and industry professionals to create “groundbreaking” advances in Life Sciences by delivering a quick, sensitive, low-cost solution.
Capital utilisation
Delta Diagnostics says it will use the funds to accelerate its goal of making rapid, sensitive, and low-cost biosensors accessible to all in order to pave the way for faster solutions in Life Sciences research.
Guy Dewil, CEO of Delta Diagnostics, says, “This investment will accelerate the launch of our first product. It will unlock the full potential of our biosensing technology to drive discoveries in Life Sciences.”
With initial funding from TNO and UNIIQ, the company has grown into a highly experienced and well-balanced team, tirelessly perfecting its biosensing technology.
Delta mentions that with the initial funding from TNO and UNIIQ, it developed a team that worked towards advancing its biosensing technology. And the latest fund will help the company to advance as its initial product launch draws near.
This will make it possible for the company and its Overijssel-region partners to continue developing next-gen biosensor devices for real-time biomolecule detection in samples.
01
How Leipzig became a hub for energy and medical tech startups with IRL and SpinLab support